Fintel reports that on June 26, 2025, B. Riley Securities initiated coverage of Capricor Therapeutics (NasdaqCM:CAPR) with a ...

Capricor Therapeutics said on Tuesday the U.S. Food and Drug Administration has indicated that an advisory panel review may ...

Capricor Therapeutics updates on Deramiocel BLA for duchenne muscular dystrophy: San Diego Thursday, June 26, 2025, 15:30 Hrs [IST] Capricor Therapeutics, a biotechnology company ...

Capricor Therapeutics shares climbed Tuesday after the Food and Drug Administration said an advisory committee meeting is not required before deciding on the company's cell therapy treatment for a ...

FDA has indicated that an Advisory Committee meeting is not required at this timeIn-person late-cycle review meeting ...

The agency said it will evaluate whether further regulatory action is needed after investigating the deaths of two patients ...

Four-year data show preservation of cardiac function, including LVEFSkeletal muscle disease progression continues to slow ...

The ouster of the FDA's chief regulator of cell and gene therapies came immediately after a disagreement with her boss over a ...

Capricor's DMD therapy Deramiocel is under FDA Priority Review with no major issues flagged; PDUFA date set for August 31, 2025.

Capricor stock drops as FDA cancels advisory meeting on Duchenne therapy; leadership changes and regulatory tensions fuel uncertainty.

Capricor Therapeutics (NASDAQ: CAPR) is a biotechnology company dedicated to advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases.

Capricor Therapeutics. FDA has indicated that an Advisory Committee meeting is not required at this time. In-person late-cycle review meeting scheduled for mid-July ...